These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38396896)
1. Assessment of the Impact of Carvedilol Administered Together with Dexrazoxan and Doxorubicin on Liver Structure and Function, Iron Metabolism, and Myocardial Redox System in Rats. Szponar J; Gorska A; Ostrowska-Lesko M; Korga-Plewko A; Tchorz M; Ciechanski E; Dabrowska A; Poleszak E; Burdan F; Dudka J; Murias M; Mandziuk S Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396896 [TBL] [Abstract][Full Text] [Related]
2. The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy. Szponar J; Ciechanski E; Ostrowska-Lesko M; Gorska A; Tchorz M; Dabrowska A; Dudka J; Murias M; Kowalczyk M; Korga-Plewko A; Mandziuk S Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373350 [TBL] [Abstract][Full Text] [Related]
3. Effect of gemfibrozil on cardiotoxicity induced by doxorubicin in male experimental rats. Haybar H; Goudarzi M; Mehrzadi S; Aminzadeh A; Khodayar MJ; Kalantar M; Fatemi I Biomed Pharmacother; 2019 Jan; 109():530-535. PubMed ID: 30551518 [TBL] [Abstract][Full Text] [Related]
4. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Miranda CJ; Makui H; Soares RJ; Bilodeau M; Mui J; Vali H; Bertrand R; Andrews NC; Santos MM Blood; 2003 Oct; 102(7):2574-80. PubMed ID: 12805055 [TBL] [Abstract][Full Text] [Related]
5. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats. Ammar el-SM; Said SA; Suddek GM; El-Damarawy SL Can J Physiol Pharmacol; 2011 Apr; 89(4):269-76. PubMed ID: 21526973 [TBL] [Abstract][Full Text] [Related]
6. Protective effect of carvedilol alone and coadministered with diltiazem and prednisolone on doxorubicin and 5-fluorouracil-induced hepatotoxicity and nephrotoxicity in rats. Akindele AJ; Oludadepo GO; Amagon KI; Singh D; Osiagwu DD Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417758 [TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 4 (TLR4) expression is correlated with T2* iron deposition in response to doxorubicin treatment: cardiotoxicity risk assessment. Trofenciuc NM; Bordejevic AD; Tomescu MC; Petrescu L; Crisan S; Geavlete O; Mischie A; Onel AFM; Sasu A; Pop-Moldovan AL Sci Rep; 2020 Oct; 10(1):17013. PubMed ID: 33046755 [TBL] [Abstract][Full Text] [Related]
8. Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity. Minotti G; Mancuso C; Frustaci A; Mordente A; Santini SA; Calafiore AM; Liberi G; Gentiloni N J Clin Invest; 1996 Aug; 98(3):650-61. PubMed ID: 8698856 [TBL] [Abstract][Full Text] [Related]
9. Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy. Zhang QL; Yang JJ; Zhang HS Biomed Pharmacother; 2019 Jan; 109():71-83. PubMed ID: 30396094 [TBL] [Abstract][Full Text] [Related]
10. Multitissue analysis of exercise and metformin on doxorubicin-induced iron dysregulation. Mackay AD; Marchant ED; Munk DJ; Watt RK; Hansen JM; Thomson DM; Hancock CR Am J Physiol Endocrinol Metab; 2019 May; 316(5):E922-E930. PubMed ID: 30888858 [TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-induced cardiotoxicity is suppressed by estrous-staged treatment and exogenous 17β-estradiol in female tumor-bearing spontaneously hypertensive rats. Pokrzywinski KL; Biel TG; Rosen ET; Bonanno JL; Aryal B; Mascia F; Moshkelani D; Mog S; Rao VA Biol Sex Differ; 2018 Jun; 9(1):25. PubMed ID: 29907135 [TBL] [Abstract][Full Text] [Related]
12. Cardiac response to doxorubicin and dexrazoxane in intact and ovariectomized young female rats at rest and after swim training. Calvé A; Haddad R; Barama SN; Meilleur M; Sebag IA; Chalifour LE Am J Physiol Heart Circ Physiol; 2012 May; 302(10):H2048-57. PubMed ID: 22447943 [TBL] [Abstract][Full Text] [Related]
13. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Matsui H; Morishima I; Numaguchi Y; Toki Y; Okumura K; Hayakawa T Life Sci; 1999; 65(12):1265-74. PubMed ID: 10503942 [TBL] [Abstract][Full Text] [Related]
14. β-Caryophyllene, a natural bicyclic sesquiterpene attenuates doxorubicin-induced chronic cardiotoxicity via activation of myocardial cannabinoid type-2 (CB Meeran MFN; Al Taee H; Azimullah S; Tariq S; Adeghate E; Ojha S Chem Biol Interact; 2019 May; 304():158-167. PubMed ID: 30836069 [TBL] [Abstract][Full Text] [Related]
18. Dexmedetomidine alleviates doxorubicin cardiotoxicity by inhibiting mitochondrial reactive oxygen species generation. Yu JL; Jin Y; Cao XY; Gu HH Hum Cell; 2020 Jan; 33(1):47-56. PubMed ID: 31643023 [TBL] [Abstract][Full Text] [Related]
19. New Insights About Doxorubicin-Induced Toxicity to Cardiomyoblast-Derived H9C2 Cells and Dexrazoxane Cytoprotective Effect: Contribution of Dallons M; Schepkens C; Dupuis A; Tagliatti V; Colet JM Front Pharmacol; 2020; 11():79. PubMed ID: 32153402 [TBL] [Abstract][Full Text] [Related]
20. Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity. Monahan DS; Flaherty E; Hameed A; Duffy GP Biomed Pharmacother; 2021 Aug; 140():111702. PubMed ID: 34015579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]